A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years

NCT01810393 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
114
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Hoffmann-La Roche